

IMPLEMENTATION OF A MULTIDISCIPLINARY CIRCUIT FOR THE MANAGEMENT OF HAEMATOLOGIC PATIENTS UNDER TREATMENT WITH BISPECIFIC ANTIBODIES

Noguera-Jurado C, Manzaneque A, Molas G, Castells G, Jara S, Tenas B, Nicolás J. Pharmacy Department. Hospital Universitari Mútua Terrassa, Spain

WHAT WAS DONE



Action plan for haematologic patients treated with bispecific antibodies (BA) for the detection and proper management of their toxicities



Cytokine release syndrome (CRS)

Immunoeffector cell-associated neurotoxicity syndrome (ICANS)

Multidisciplinary action

- Ensure adequate management of toxicities
- Guarantee patient safety

HOW IT WAS DONE


Multidisciplinary team



Pharmacy, Haematology, Nursing, Intensive Care Medicine and Neurology

Action circuit

Detection and management of toxicities



Specific protocol for TOCILIZUMAB



Within pharmacy service hours: centralization of preparation in pharmacy department




Outside pharmacy service hours: Preparation in the hospitalization ward by trained professionals using a **kit** previously prepared by the pharmacist

WHAT HAS BEEN ACHIEVED











ELRANATAMAB (4/5) / TECLISTAMAB (1/5)

- 3 patients presented grade 1 CRS: resolved with symptomatic therapy
- 1 patient presented grade 1 ICANS: only required monitoring

The availability of the toxicity management circuit, and the staff training, allowed toxicities to be detected and resolved early and, if tocilizumab had been needed, the circuit would have ensured its immediate availability.

WHAT HAS BEEN ACHIEVED

The implementation of a multidisciplinary care circuit led by pharmacy and haematology guarantees the adequate management of toxicities associated with the treatment, ensuring the best quality of care for the patients and their safety.



